Incretin Mimetics in the Indian Context: Revisiting Exenatide

[1]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[2]  P. Katulanda,et al.  Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force , 2019, Diabetes Therapy.

[3]  A. Mølck,et al.  The Human GLP-1 Analog Liraglutide and the Pancreas , 2012, Diabetes.

[4]  B. Hoogwerf,et al.  Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies , 2010, Diabetes Care.

[5]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[6]  S. Aronoff,et al.  Glucose Metabolism and Regulation: Beyond Insulin and Glucagon , 2004 .

[7]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[8]  G. Umpierrez,et al.  Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults , 2004, International Journal of Obesity.

[9]  D. Drucker.  Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. , 2003, Endocrinology.

[10]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[11]  A. Singh.  Incretin response in Asian type 2 diabetes: Are Indians different? , 2015, Indian journal of endocrinology and metabolism.